This lecture was supported by Grant Number 6H79FG000999-01M001 from SAMHSA. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of SAMHSA.  

About the speaker

Mark Hyman Rapaport, MD, Professor, joined the department January 1, 2021 as new Chairman of the Department of Psychiatry and CEO of the Huntsman Mental Health Institute (HMHI). Dr. Rapaport serves as the second William H. and Edna D. Stimson Presidential Endowed Chair, University of Utah School of Medicine.

From 2011-2020, Dr. Rapaport was Chairman of the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine and Chief of Psychiatric Services at Emory Healthcare in Atlanta, Georgia. Prior to that appointment, he was the Chairman of Psychiatry and Behavioral Neurosciences at Cedars-Sinai Medical Center and a Professor of Psychiatry at both Cedar-Sinai and the David Geffen School of Medicine at UCLA. He was the first holder of the Polier Chair while at Cedars-Sinai and also previously served as Director of the Mental Health Outpatient Clinical Research Center in the Department of Psychiatry at University of California, San Diego. He served as the first Chair of the National Institute on Drug Abuse (NIDA) Clinical Trials Network's Data Safety Monitoring Board and Chair of its Special Review Committee and also serves on NIH and NIMH Review Committees.

Dr. Rapaport has received peer-reviewed grant funding from the National Institute of Mental Health (NIMH), the National Center for Complimentary and Alternative Medicine, The Stanley Medical Research Institute, the Veterans Affairs Research Board and the National Alliance for Research on Schizophrenia and Depression (NARSAD) Foundation. His research interests focus on human psychoneuroimmunology, psychopharmacology research, clinical trial methodology, quality of life, and complementary and alternative medicine. Dr. Rapaport has trained and mentored students, physicians and researchers in the fields of psychopharmacology, outcomes research, and psychoneuroimmunology for over 30 years.

Disclosure Statements

Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she has with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt, and if there will be discussion of any products, services, or off-label uses of product(s) during this presentation.

Mark Hyman Rapaport, MD, reports that he has no relationships with any entity producing, marketing,  selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. He will not discuss any products, services, or off-label uses in this presentation.

Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months: Todd Peters, MD, Deepak Prabhakar, MD, Elizabeth Ryznar, MD, MSc., Louis Marino, MD, Ehsan Syed, MD, Devi Bhuyan, PhD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Stacey Garnett, RN, MSN, Stephanie M. Robinson, MSN, RN, PMH-BC, NPD-BC, NE-BC, Heather Billings, RN, Lisa Illum, MLIS, MEd, and Jennifer Tornabene.